IPC Signs Twin MoUs with PMBI, NIPER Hajipur to Strengthen Drug Quality, Research and Patient Safety
The IPC–PMBI partnership aims to strengthen quality assurance of medicines distributed through Pradhan Mantri Bhartiya Janaushadhi Kendras, with random batch testing by IPC, while also promoting adoption of the National Formulary of India to encourage rational use of medicines.
Both organisations will jointly conduct training and awareness programmes for pharmacists and stakeholders on rational drug use, pharmacovigilance practices and public health responsibilities.
New Delhi: Indian Pharmacopoeia Commission has signed two strategic memoranda of understanding with Pharmaceuticals and Medical Devices Bureau of India and National Institute of Pharmaceutical Education and Research Hajipur to enhance drug quality assurance, promote pharmaceutical research and strengthen patient safety frameworks.
The partnership between IPC and PMBI focuses on improving the quality of medicines distributed through Pradhan Mantri Bhartiya Janaushadhi Kendras. Under the arrangement, PMBI will submit randomly selected drug batches to IPC for testing, strengthening the quality assurance ecosystem.
The collaboration will also promote the adoption of the National Formulary of India across Janaushadhi Kendras to encourage rational use of medicines. Pharmacovigilance efforts will be expanded through wider visibility of the Pharmacovigilance Programme of India, including QR codes and helpline access to improve reporting of adverse drug reactions.
Both organisations will jointly conduct training and awareness programmes for pharmacists and stakeholders on rational drug use, pharmacovigilance practices and public health responsibilities.
The MoU with NIPER Hajipur is aimed at advancing pharmaceutical research, academic collaboration and capacity building. The institute will work with IPC on areas such as impurity profiling, including genotoxic impurities like nitrosamines, and their linkage with adverse drug reaction data to establish evidence-based pharmacopoeial standards.
The collaboration will also focus on developing analytical methods, quality control protocols and reference standards for biologics, biosimilars and emerging therapies such as cell and gene treatments for inclusion in the Indian Pharmacopoeia.
In addition, the partnership includes faculty exchange, joint research publications, training programmes and access to advanced analytical infrastructure, along with internship and fellowship opportunities for students.
The twin agreements are expected to strengthen India’s pharmaceutical quality ecosystem, enhance regulatory science and reinforce patient safety, while supporting innovation in healthcare standards.
